Theralase(r) closes $can 750,000 non-brokered private placement

Toronto, on / accesswire / april 24, 2024 / theralase® technologies inc. ("theralase® " or the "company") (tsxv:tlt)(otcqb:tltff)(fra:ttx), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated photo dynamic compounds ("pdcs") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement ("nbpp") offering ("offering") of units ("units"). on closing, the corporation issued an aggregate of 4,167,778 units at a price of $can 0.18 per unit for aggregate gross proceeds of approximately $can 750,200.
CAN Ratings Summary
CAN Quant Ranking